Vertex Has Good News and Exelixis Is Reinforcing Its Outperformance

Vertex Product Kalydeco Has Good News
Vertex Pharmaceuticals' Product Kalydeco for CF in Young Children

Good news for Vertex (VRTX) product Kalydeco® (ivacaftor) is the first cystic fibrosis (CF) product to be prescribed for children ages six months to less than 12 months. Beneficiary children are those who have at least one mutation in their CF transmembrane conductance regulator (CFTR) gene that is responsive to Kalydeco, based on clinical and . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.